Skip to main content

NIGMS Grant Funds Insilicos' Software Development

NEW YORK (GenomeWeb News) — Insilicos has been awarded a grant from the National Institutes of Health in order to study a statistical methodology that can be applied to biomedical research, the company said yesterday.

The company will use the roughly $400,000 in funds from the National Institute of General Medical Sciences to continue developing a technique called Least Angle Regression, or LARS, which is used to produce stable predictions from data with a large number of dimensions.

"LARS is showing exciting results in life science and other areas," Insilicos CEO Erik Nilsson said in a statement.

Nilsson said the company takes a system biology approach toward disease diagnosis in areas "where we see disease as a breakdown of molecular communication in the body. When you measure this breakdown, you have lots of different signals to choose from, different molecules you can measure. We use LARS as a way of selecting the most promising signals and using these signals to predict disease."

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.